Dr. Jürgen Schumacher, Chief Executive Officer
Jürgen Schumacher is one of Germany’s leading biotech entrepreneurs with more than 25 years’ experience in the industry. He is a Boardmember of many companies but mostly those involved in the biotech industry. Jürgen was co-founder of Qiagen and acted as spokesperson for the board. He has founded many companies in Germany including NewLab BioQuality which was sold (2008) to a large US company. Moreover, he is a member of numerous biotech associations and is a consultant for the biotechnology activities in North Rhine Westphalia.
Stefan Fischer, Chief Financial Officer
Stefan Fischer has a degree in Business Administration and more than 15 years of experience in the life science and biotech industries. Stefan was previously the CFO of NewLab BioQuality, the biopharmaceutical analytics company founded by Dr. Schumacher, which was acquired by a large US company.
Dr. Guido Koopmans, Head of Research & Development
Guido holds a PhD in neuroscience from the University of Maastricht (The Netherlands). He has gained scientific experience across a spectrum of CNS therapeutic areas including pain, neurotrauma and degeneration, dementia and depression. He has extensive experience in preclinical and early clinical development of therapeutic drugs for neuropathic pain and spinal cord injury. His research is documented in over 30 publications including manuscripts, abstracts and patents. Guido is co-founder of Algiax and is actively involved in the fundraising for Algiax.
Dr. Birgit Hasse, Associate Head of Research & Development
Birgit Hasse is a neuroscientist with a degree in biology and PhD from Düsseldorf University. She has more than 12 years of experience in preclinical and early clinical drug development and project management. Birgit is co-founder of Algiax and was actively involved in the fundraising for Algiax. Birgit has patented several development candidates in neuropathic pain and trauma-related disorders of the nervous system.